Elevance Health Inc. (ELV) Stock Analysis

37.0/100
Sell Not Halal Healthcare
Price $429.69
Market Cap $92.84B
52-Week Change +30.89%

Is ELV a good investment?

Elevance Health Inc. (ELV) has a Plutrex AI rating of 37.0/100 as of November 06, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: Balance sheet fortress: $37.85B cash, D/E 0.68 (8.4% below peer avg 0.743), FCF $6.51B — unmatched liquidity eliminates solvency risk and supports dividends/buybacks through any earnings trough. Main concern: Extreme growth-adjusted overvaluation that WORSENED: PEG rose from 3.96 to 4.03 as the stock price increased faster than EPS estimate revisions; at peer-average PEG of 1.74x on 4.55% 5-year growth, fair P/E is ~7.9x implying fair value of ~$180-$210; even at a generous 2.0x PEG, fair value is only ~$240; current $432 represents 50-60% downside to growth-adjusted fair value.

Investment Summary

ELV at $432.00 remains a SELL. The core thesis is unchanged from 9 days ago: a structurally growth-impaired managed care insurer priced for a growth profile it no longer delivers. The stock has actually risen $10.51 (+2.5%) since the prior report, moving further away from fair value rather than toward it. Key numbers: PEG of 4.03 (WORSENED from 3.96) vs. peer average 1.74 — investors pay 131.9% more per unit of growth than the typical peer. Forward EPS growth of 4.12% next year and 4.55% over 5 years vs. industry averages of 18.11% and 16.44% respectively — ELV grows at roughly one-quarter the pace of peers. P/E of 18.35x on sub-5% growth is indefensible by any standard valuation framework. Balance sheet remains a genuine fortress: $37.85B cash, D/E 0.68 vs. peer avg 0.743, FCF of $6.51B — this stock will not blow up, but it is significantly overvalued relative to its growth trajectory. News sentiment is strongly positive (91/100, 10 of 12 articles positive), headlined by Q3 adjusted EPS of $6.99 beating expectations and a lifted 2026 profit forecast on better medical cost management. The CVS breakup narrative provides a modest relative-positioning tailwind. None of this resolves the fundamental overvaluation. Fair value: $280-$340. Current price: $432.00. Gap is too wide to hold or buy.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
72/100
Growth Potential
15/100
Valuation
19/100
Profitability
38/100
Debt Management
74/100
Analyst Sentiment
58/100
Technical Momentum
42/100
Insider Confidence
45/100
News Sentiment
74/100

Fundamental Analysis

ELV's fundamentals confirm a high-quality operator in a structurally disadvantaged valuation position. Profitability: Operating margin 4.219% (beats peer avg 3.966% by 6.4%); Net margin 2.55% (beats peer avg 2.011% by 26.8%); ROE 11.6% (beats peer avg 10.997% by 5.5%). These are genuine competitive advantages but they are incremental, not transformational. Financial Health: D/E 0.68 vs. peer avg 0.743 (conservative leverage); $37.85B total cash; FCF $6.51B — balance sheet is fortress-grade and unambiguously a strength. Growth (the critical failure): Revenue growth 1.4% vs. peer avg 4.46% (-69% gap); forward next-year EPS growth 4.12% vs. peer avg 18.11% (-77% gap); 5-year EPS CAGR 4.55% vs. peer avg 16.44% (-72% gap); YoY EPS growth -1.1% — per-share earnings are literally declining. Valuation: P/E 18.35x (vs. peer avg 21.54x, a 14.8% discount that is misleading given the growth gap); PEG 4.03x (vs. peer avg 1.74x, a 131.9% PREMIUM — this is the definitive overvaluation signal). At 5-year EPS growth of 4.55%, a fair PEG of 1.74x (industry norm) implies a justified P/E of only ~7.9x. Even at a generous defensive premium PEG of 2.0x, the implied fair P/E is ~9.1x — still less than half of the current 18.35x. P/B of 2.08x is reasonable. Analyst consensus target $475.25 implies 10.0% upside, modest and insufficient reward for the fundamental risk.

News Sentiment

Elevance Health is sending mixed signals to investors, and Wall Street is trying to decide what to make of it all. The managed care giant — which covers millions of Americans through Medicaid, Medicare, and commercial insurance plans — delivered a solid third quarter, with adjusted earnings of $6.99 per share beating the company's own expectations. Better yet, management turned around and lifted its 2026 profit forecast, crediting tighter medical cost management. That's the kind of execution story investors love to hear. But there's a subplot making Elevance look even better by comparison: rival CVS Health sent shockwaves through the healthcare sector by announcing plans to split into two companies, sending its stock tumbling 12%. As CVS scrambles to reorganize, some investors are quietly rotating into Elevance as the more stable, cohesive alternative for employer and government health contracts — a potential tailwind the company didn't have to earn. On the flip side, Elevance isn't without headaches. Medical membership declined during the quarter — a real drag on the core insurance engine. And a lawsuit over $160 million in allegedly misleading claims against an autism-therapy provider highlights the ongoing fraud risks inherent in managing vast healthcare networks. For long-term investors, the story boils down to this: Elevance is a well-run company in a tough spot, growing far slower than its managed care peers while still carrying a valuation that assumes better days ahead. The 2026 profit upgrade is encouraging — but the stock needs to get cheaper before the math works in buyers' favor.

Risk Assessment

PRIMARY RISK (to the SELL thesis): The 2027 management commitment of 12%+ adjusted EPS growth from a $26.75+ baseline is the key upside risk — if Carelon outperforms and medical cost ratios stabilize ahead of schedule, forward estimates could be revised sharply upward, compressing the PEG and justifying a higher multiple. The CVS breakup narrative could also accelerate employer plan contract wins for ELV. DOWNSIDE RISKS (supporting SELL): (1) Medical cost ratio deterioration — with operating margin of only 4.2%, a 50-100bp MCR uptick would severely impact earnings; (2) Medicare Advantage rate pressure — CMS rate setting has been a persistent headwind; (3) Medicaid redetermination overhang — membership declined (noted in key developments), reducing the revenue base; (4) Competitive pressure — peers growing revenue 4.46% vs. ELV's 1.4% suggests potential share loss. MITIGATION: ELV's balance sheet ($37.85B cash, $6.51B FCF) means the downside scenario is 'underperformance vs. peers,' not solvency risk. For those forced to hold, the balance sheet provides a floor. For new buyers: wait for $290-$320 zone where risk/reward finally becomes attractive.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is ELV a halal stock?

No, Elevance Health Inc. (ELV) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for ELV?

Elevance Health Inc. (ELV) has a Plutrex AI rating of 37.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is ELV a good investment?

According to Plutrex AI, ELV has a Sell rating (37.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in ELV?

US stocks like ELV can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in ELV?

Plutrex AI identifies the main risks for ELV by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about ELV

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open ELV in ElBarake